Virexa Biopharma, a mid-cap pharmaceutical research firm, reported an EBITDA of $135 million for FY25, marking a 12% year-over-year growth driven by strong progress in its oncology drug pipeline. The company recently secured $78 million in Series D funding, aimed at expanding clinical trial infrastructure in Southeast Asia. With a solid Return on Equity (ROE) of 18.7%, the company reflects efficient use of shareholder capital. Virexa maintains a debt-to-equity ratio of 0.45, signaling prudent leverage. A standout metric is its R&D expenditure, which accounts for 19.2% of total revenue, significantly above the industry average and not tracked by others here.